Quote:A Clue for the Clueless GOP
Since the day Trump was inaugurated, we have been told by the Republican spokes-mouths in the media that this whole Russia investigation/Comey firing/inane tweets/Kushner back-channels/Flynn collusion/voter fraud – need I go on? – topics are being raised by godless libruls in order to keep Idiot Boy from the important task of pursuing his agenda to “make America great again”.
Here’s a hint: TRUMP HAS NO AGENDA. He has absolutely no idea what is in any bill being advanced by Republicans. He is completely ignorant of anything that is going on in the country he pretends to lead. He has no interest in doing anything that keeps him away from his Twitter account, his TV, and his golf game.
He is not being distracted from doing anything. On the contrary; he himself is trying to distract you GOPers – and the nation at large – from the obvious fact that he has no idea whatsoever what he’s doing.
The truth is that Mr. Tangerine Man persists in “fighting back ten times harder” against everything – from honest reporting of the many investigations into his probable criminal activity to perceived personal slights – because it distracts YOU from the obvious: He can’t do the job he was elected to do, and he’s hoping that with all of the “distractions” he allegedly has to deal with, you simply won’t notice how totally incompetent he is, and how completely uninterested he is in the responsibilities of his office.
The over-arching truth is that Trump isn’t being distracted from the duties of his office, as evidenced by the fact that he himself is the root cause of those “distractions”. He has consistently doubled-down when challenged, and has constantly throw gasoline on even the smallest fires – anything that provides an excuse for spending his days tweeting nonsense instead of attending to the nation’s business.
I might remind Republicans that when Bill Clinton was under investigation for Whitewater, and later for his relationship with Monica Lewinsky, he continued to govern a nation and fulfill the duties of POTUS. He did not spend his days publicly maligning his detractors – and he certainly didn’t abandon his responsibilities by claiming that he was “distracted” from doing so due to what was going on in the media.
Face it, Republicans. You elected an incompetent idiot to the highest office in our country, and he continues to demonstrate that incompetence on a daily basis. He quickly figured out that if he finds – or more to the point, actually creates – enough distractions from that incompetence, you’ll be too busy looking the other way to realize just how unfit for office he apparently is.
Trump’s “presidency” is a classic case of there being no “there” there – no intellect, no common sense, no decency, no sense of responsibility, no ability to lead, no interest in the country or its citizens – no ability to even recognize that when you’re at the bottom of a hole, it’s a good idea to stop digging.
Well, you Republicans can huff and you can puff about how your Little Piggy is a poor, defenceless victim – when everyone knows it’s his own self-generated pigshit that has put him in that easily-blown-down house.
The reality is that your so-called pResident’s behaviour has proven that huffing and puffing is all he’s capable of doing. And your continued defense of his idiocy is, if nothing else, incredibly entertaining.
Oh, and by the way – the minute your rhetoric changed from the investigations into Trump’s collusion with the Russians being "unfounded allegations" to being “not a crime if it happened”, you gave yourselves away. It’s sad enough that you are trying to defend a traitor – the fact that you are more than willing to do so speaks for itself.
NanceGreggs (22,589 posts)
A Clue for the Clueless GOP Since the day Trump was
Top 10 Most Recent News Articles
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Continue Reading
Community in Shock After Fatal Bakersfield Shooting
The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...
Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue ReadingFirefox Champions Privacy with Iconic Internet Campaign
Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...
Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC
Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...
Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026
Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....
Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event
Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...
Continue ReadingTop 5 Most Recently Viewed Articles
Mobility Direct's Inspiring Journey in Supporting the Disabled
Empowering Mobility for a Decade Mobility Direct has reached a remarkable milestone, celebrating ten years of dedicated service to individuals facing mobility challenges. The company, based in Florida, has profoundly impacted the lives of many by providing free mobility scooters to those in need. With each scooter given, they challenge the common assumption that mobility...
Continue Reading
GARDANT GLOBAL Teams Up with GovConRx for Enhanced Services
GARDANT GLOBAL Forms Strategic Alliance with GovConRx GARDANT GLOBAL is thrilled to share exciting news about its latest partnership with GovConRx. This collaboration is set to transform the landscape of contract performance management for government contractors. GovConRx, well-known for its expertise in enhancing CPARS ratings, will significantly augment GARDANT's...
Continue Reading
Text Request and Commify Join Forces to Enhance Messaging Solutions
Text Request and Commify Join Forces to Enhance Messaging Solutions Text Request, a leader in the business text messaging domain, has recently announced an exciting new chapter following its acquisition by the U.K.-based Commify. This strategic move is aimed at expanding its reach within the U.S. market while maintaining its operational base in Chattanooga. Growth Journey...
Continue Reading
Agenus Investors Alerted on Class Action Lawsuit Developments
Levi & Korsinsky Notifies Investors of Class Action for Agenus Inc. Levi & Korsinsky, LLP is reaching out to investors in Agenus Inc. (NASDAQ: AGEN) regarding a significant class action lawsuit that may impact those financially affected by the company's alleged misrepresentations. This development is crucial for stakeholders who have invested in Agenus during the...
Continue Reading
Savvas Unveils Innovative Science Curriculum for Students
Introducing Experience Science for Grades K-8 In a groundbreaking initiative, Savvas Learning Company has launched Experience Science, an all-new program curated specifically for students in grades K-8. This innovative curriculum aims to engage young learners in scientific concepts, placing significant emphasis on hands-on experiences driven by real-world phenomena....
Continue Reading